Literature DB >> 3992249

Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation.

D C Mash, D D Flynn, L T Potter.   

Abstract

Cerebral cortex samples from patients with Alzheimer's disease and from rats after experimental cholinergic denervation of the cerebral cortex exhibited reductions in the presynaptic marker choline acetyltransferase activity and in the number of M2 muscarine receptors, with no change in the number of M1 receptors. These results are in keeping with evidence that M2 receptors function in cholinergic nerve terminals to regulate the release of acetylcholine, whereas M1 receptors are located on postsynaptic cells and facilitate cellular excitation. New M1-selective agonists and M2-selective antagonists directed at post- or presynaptic sites deserve consideration as potential agents for the treatment of the disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3992249     DOI: 10.1126/science.3992249

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  88 in total

1.  The M1 muscarinic agonist CI-1017 facilitates trace eyeblink conditioning in aging rabbits and increases the excitability of CA1 pyramidal neurons.

Authors:  C Weiss; A R Preston; M M Oh; R D Schwarz; D Welty; J F Disterhoft
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

2.  Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice.

Authors:  Weilie Zhang; Anthony S Basile; Jesus Gomeza; Laura A Volpicelli; Allan I Levey; Jürgen Wess
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

3.  Metrifonate and dichlorvos: effects of a single oral administration on cholinesterase activity in rat brain and blood.

Authors:  V Hinz; S Grewig; B H Schmidt
Journal:  Neurochem Res       Date:  1996-03       Impact factor: 3.996

4.  Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's dementia.

Authors:  E D London; M J Ball; S B Waller
Journal:  Neurochem Res       Date:  1989-08       Impact factor: 3.996

5.  Stability of clinical condition in mild cognitive impairment is related to cortical sources of alpha rhythms: an electroencephalographic study.

Authors:  Claudio Babiloni; Giovanni B Frisoni; Fabrizio Vecchio; Roberta Lizio; Michela Pievani; Geroldi Cristina; Claudia Fracassi; Fabrizio Vernieri; Guido Rodriguez; Flavio Nobili; Raffaele Ferri; Paolo M Rossini
Journal:  Hum Brain Mapp       Date:  2010-12-22       Impact factor: 5.038

6.  Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease.

Authors:  T T Soncrant; K C Raffaele; S Asthana; A Berardi; P P Morris; J V Haxby
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Effects of disrupting the cholinergic system on short-term spatial memory in rats.

Authors:  J S Andrews; J H Jansen; S Linders; A Princen
Journal:  Psychopharmacology (Berl)       Date:  1994-08       Impact factor: 4.530

Review 8.  Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release.

Authors:  R Quirion
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

9.  Sources of cortical rhythms in adults during physiological aging: a multicentric EEG study.

Authors:  Claudio Babiloni; Giuliano Binetti; Andrea Cassarino; Gloria Dal Forno; Claudio Del Percio; Florinda Ferreri; Raffaele Ferri; Giovanni Frisoni; Silvana Galderisi; Koichi Hirata; Bartolo Lanuzza; Carlo Miniussi; Armida Mucci; Flavio Nobili; Guido Rodriguez; Gian Luca Romani; Paolo M Rossini
Journal:  Hum Brain Mapp       Date:  2006-02       Impact factor: 5.038

10.  In vivo competition studies of Z-(-,-)-[125I]IQNP against 3-quinuclidinyl 2-(5-bromothienyl)-2-thienylglycolate (BrQNT) demonstrating in vivo m2 muscarinic subtype selectivity for BrQNT.

Authors:  V I Cohen; B R Zeeberg; S F Boulay; V K Sood; M R Rayeq; R A Danesh; D W McPherson; R C Reba
Journal:  J Mol Neurosci       Date:  1998-08       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.